Eli Lilly and Company (LLY)

Cash ratio

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Cash and cash equivalents US$ in thousands 3,268,400 3,369,000 3,223,600 2,460,200 2,818,600 2,380,800 2,694,500 3,545,900 2,067,000 2,617,400 2,622,900 2,459,200 3,818,500 3,788,200 3,220,000 3,002,400 3,657,100 3,595,300 2,365,100 1,699,000
Short-term investments US$ in thousands 154,800 149,400 140,400 126,100 109,100 113,100 134,600 123,400 144,800 124,700 113,800 109,100 90,100 37,100 51,200 49,000 24,200 35,000 22,800 78,400
Total current liabilities US$ in thousands 28,376,600 24,674,100 27,121,200 18,598,100 27,293,200 21,998,200 18,915,000 16,010,000 17,138,200 15,652,800 15,620,600 13,386,000 15,052,700 13,682,000 15,093,200 11,714,200 12,481,600 11,976,900 11,988,500 12,610,200
Cash ratio 0.12 0.14 0.12 0.14 0.11 0.11 0.15 0.23 0.13 0.18 0.18 0.19 0.26 0.28 0.22 0.26 0.29 0.30 0.20 0.14

December 31, 2024 calculation

Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($3,268,400K + $154,800K) ÷ $28,376,600K
= 0.12

The cash ratio of Eli Lilly and Company has fluctuated over the periods provided. It was relatively low at around 0.14 to 0.20 in the first half of 2020, indicating that the company had limited cash readily available to cover its short-term obligations. However, the ratio improved in the latter half of 2020 and into 2021, reaching a peak of 0.30 in September 2020, suggesting stronger liquidity position.

Subsequently, the cash ratio dipped back to the mid-0.20s and 0.10s range in the following periods, implying a slight decline in the company's ability to meet its short-term liabilities solely with cash on hand. By the end of 2024, the cash ratio had leveled off around 0.12 to 0.14, indicating that Eli Lilly may need to monitor its liquidity position to ensure it has enough cash to cover its short-term obligations.


See also:

Eli Lilly and Company Cash Ratio (Quarterly Data)